TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > BREXIT Updates > BREXIT: Pharmaceutical Products and Import/Export – Key Changes

BREXIT: Pharmaceutical Products and Import/Export – Key Changes

PharmaLexperts – taking a pragmatic approach to Brexit….

On 01 September 2020, MHRA laid out the future requirements for placing medicines on the UK market after the end of the Brexit transition period on 31 December 2020.  Our team which includes SMEs from the UK and the EU, are here to work with you to map out the impact on your operations and offer cohesive, practical solutions to assist you with a smooth transition.

 

Key Changes for Pharmaceutical Products and Import/Export

  • Centrally Authorised Market Authorisations (CAP MAs):  CAP Mas will automatically be converted into GB MAs (England, Wales & Scotland) on 01 January 2021, existing CAPs will remain valid for marketing products in Northern Ireland.  Once the required GB MAs are issued then the MA Holder will have 24 months from the end of transition to submit appropriate amended artwork and a further 12 months (36 months total) to then transition to releasing stock in compliant packaging with the PLGB Authorisation numbers on the packaging.
  • Parallel Distribution Notices/Parallel Import Licences: Parallel Distribution Notices (PDNs) will no longer be valid in Great Britain (Excluding NI) and will be replaced by Parallel Import Licences (PIL) which will allow the products to be marketed in Great Britain only.
  • Responsible Person (Import): From 01 January 2021, a wholesale dealer in Great Britain (excluding NI) may only import Qualified Person (QP) certified medicines from the European Economic Area (EEA) if certain checks are made by the ‘Responsible Person (import) (RPi)’.  The new guidance has given clarity in that products sourced from Northern Ireland to Great Britain for wholesale purposes are permitted under the supervision of a Responsible Person (RP) and do not require an RPi.
  • Wholesale Distribution Authorisation Holder: New timelines are also included on updating the WDA and notifying the MHRA on the intention to continue to import from a country which is on the MHRA’s approved country for import list.  WDA holders should now notify MHRA in writing before 01 July 2021 of their intention to continue to import medicinal products from a country on the list, and they must submit a change to their WDA licence before 01 January 2023 to list a Responsible Person (import) (RPi) who will carry out those specific functions.
  • Continuity of Supply: Pharmaceutical MIA and WDA holders now need to familiarise themselves with these revised rules to start preparing their QMS and operations for the upcoming changes, ensuring a smooth transition and continuity of their import/export business.
  • Approved Country for import list: RPis are not required if a medicine is imported from an approved country for import list (currently EEA), is not licenced in the UK or the listed country and is intended as special medicinal product or is an Introduced Medicine (Intended for onward export).  In these cases the WDA holder must notify the MHRA in writing before 01 July 2021 of their intention to continue to only import medicinal products from the listed country, to which this exemption applies.

 

In all other circumstances a WDA is required including If you source a medicine without an authorisation in UK or Great Britain from Northern Ireland for supply to the Great Britain market.

  • Active Substances: Written confirmation will be required from 01 Jan 2021 for each shipment of Active Substances manufactured in Great Britain that is exported to the EEA or Northern Ireland.

 

We will follow up with additional details/clarifications as more information becomes available and, in the meantime, please feel free to contact us at brexitsupport@pharmalex.com  for additional information.

Related posts
Key Takeaways from the PDA Europe Annex 1 Workshop
Key Takeaways from the PDA Europe Annex 1 Workshop
7th June 2022
NLS DAYS 2022
NLS DAYS 2022
September 28 - May 29th, 2022
Addressing Limitations of Sterility Testing
Addressing Limitations of Sterility Testing
9th May 2022
Are virtual audits sustainable post-pandemic?
Are virtual audits sustainable post-pandemic?
6th May 2022
Orphan Drug Designation: Securing the Significant Benefits
Orphan Drug Designation: Securing the Significant Benefits
28th March 2022
Virtual Audits: To be, or not to be, that is the question
Virtual Audits: To be, or not to be, that is the question
26th January 2022
Search
Upcoming Webinars

June 16th, 2022

Better information, better decisions for your access strategy – Inmediata powered by SmartPHLEX a new platform

2:30 PM CET

June 28th, 2022

eCTD in Australia: key steps to start a successful submission

08:30 am CET / 4:30 pm AEST

June 30th, 2022

Transforming the drug development process with an integrated strategy

03:00 PM CET

Upcoming Events

June 23rd, 2022

PDA Ireland: Data Integrity

June 19 - 23rd, 2022

DIA 2022 – Reconnect with Your Life Sciences Community Live in Chicago

Visit us at booth #1515

Categories
  • All News
  • Webinars
  • Events
Archive
Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
8 Jun

Mark A Lane, PhD latest blog here https://lnkd.in/ejDdywz3 explores Integrated Product Development approaches to accelerate drug development.

To find out more register for our IPD webinar https://lnkd.in/eijUBJM5

#pharmadrugdevelopment
#webinar
#biopharmaceutical

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • Highly competent, knowledgeable, absolutely reliable and dedicated to the projects

    Europe based medium-sized biotech development company
    Senior Director
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.






    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for